The virus is the leading cause of chronic liver disease.
Typically, only 15 percent to 20 percent of patients who get interferon are rid of all signs of the virus.
Food and Drug Administration approved a new approach, a combination of interferon and ribavirin.
Nearly 100 million people worldwide, including 4 million Americans, are believed to be have hepatitis C.
At least 2.7 million Americans carry the hepatitis C virus, making it the most common blood-borne infection in the United States.
, was approved in June only for patients who had relapsed after taking interferon drugs, the only other approved
